Evidence map›Paper›PMID 23748177›Full record

ArticleInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society2013

Risk factors for ovarian cancers with and without microsatellite instability.

Yakir Segev, Tuya Pal, Barry Rosen, John R McLaughlin, Thomas A Sellers, Harvey A Risch, Shiyu Zhang, Sun Ping, Steven A Narod, Joellen Schildkraut

RetractedOpen access · greenAbstract readComparative StudyRetracted Publication
In one paragraph

Article in International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. PARP Inhibitor Insensitivity toJCO precision oncology · 2022
    Article
  3. Promoter polymorphism of FASL confers protection against female-specific cancers and those of FAS impact the cancers divergently.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015
    Article
  4. Endometriosis and ovarian cancer: links, risks, and challenges faced.International journal of women's health · 2015
    Review
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Yakir SegevFamilial Breast Cancer Research, Women's College Research Institute, Toronto, Ontario, Canada.
Tuya Pal
Barry Rosen
John R McLaughlin
Thomas A Sellers
Harvey A Risch
Shiyu Zhang
Sun Ping
Steven A Narod
Joellen Schildkraut
Moffitt Cancer Center · USMount Sinai Hospital · CAUniversity of Toronto · CAYale University · US

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI KENNETH Lynn WRIGHT · 1998 to 2026
$93.5M
Ovarian Cancer and Mismatch Repair DeficiencyR01CA111914 · NCI · H. LEE MOFFITT CANCER CTR &RES INST · PI PAL, TUYA · 2005 to 2009
$2.2M
Clinical Relevance of Mismatch Repair in Ovarian CancerK07CA108987 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI PAL, TUYA · 2006 to 2010
$664k
NCI NIH HHS K07 CA108987NCI NIH HHS P30 CA076292NCI NIH HHS R01 CA111914
6 · The paper itself

Abstract

objectiveThe objective of this study was to evaluate the association between microsatellite instability (MSI) status and (1) ovarian cancer risk factors and (2) the distribution of the specific histologic subtypes in a population-based sample of epithelial ovarian cancers.

methodsParticipants were drawn from 3 population-based studies of primary epithelial ovarian cancer. Tumor DNA was analyzed using 5 standardized microsatellite markers to assess MSI status. Patients were divided into 3 groups (MSI-high, MSI-low, and MSI-stable) according to National Cancer Institute criteria. We compared the prevalence of specific known risk and protective factors among the 3 subgroups, including body mass index, smoking history, parity, BRCA1 and BRCA2 mutation status, past oral contraceptive use, and tubal ligation. Similarly, we compared the distribution of the histologic subtypes among the 3 subgroups.

resultsA total of 917 ovarian cancer patients were included. One hundred twenty-seven (13.8%) cancers were MSI-high. Subgroup analyses according to smoking, body mass index, parity, past oral contraceptive use, and past tubal ligation did not reveal any statistically significant differences among the groups. Among the 29 patients with BRCA1 mutations, 20.7% had MSI-high cancers compared with 5.9% among 17 BRCA2-mutation patients. The proportions of different ovarian cancer histologic findings among the various MSI subgroups were similar.

conclusionsThe prevalence of risk and protective factors among ovarian cancer patients is similar for cancers with and without MSI. The distributions of MSI do not differ significantly among ovarian cancers with different histologic findings. Ovarian cancer patients with BRCA1 mutations had a 21% rate of MSI-high tumors, compared with 6% among patients with BRCA2 mutations, but this difference was not statistically significant.

Indexed as

Microsatellite InstabilityAdenocarcinoma, Clear CellAdenocarcinoma, MucinousCanadaCarcinoma, PapillaryCohort StudiesCystadenocarcinoma, SerousEndometrial NeoplasmsFemaleFollow-Up StudiesHumansMiddle AgedNeoplasm StagingOvarian NeoplasmsPrognosisRisk Factors

Identifiers

PMID23748177
PMCPMC3740723
OpenAlexW1967147743

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.